Researchers have recruited the first vaccine candidates to one of two new prevention trials that seek to immunize high-risk individuals against cancers associated with Lynch syndrome, the most common cause of hereditary colorectal cancer. Individuals who inherit the condition have an estimated… read more
POSTED: 02/08/2023
SOURCE: Cancer Prevention Science Blog
Chemopreventive Agent Development Research Group, Division of Cancer Prevention
The National Cancer Institute (NCI), Division of Cancer Prevention (DCP), is seeking a Program Director to manage the formulation, production and distribution of small molecule and biologic agents for preclinical and… read more
POSTED: 01/12/2023
SOURCE: DCP News
The National Cancer Institute’s (NCI’s) Board of Scientific Advisors (BSA) recently approved two new concept proposals aimed at expanding potential prevention interventions.
POSTED: 01/10/2023
SOURCE: Cancer Prevention Science Blog
POSTED: 12/13/2022
SOURCE: https://cbiit.webex.com/
April 8-13, 2022
DCP/PREVENT-funded Project Presentations
Session OPO.IM01.01 - Tumor Immunobiology
5631 - Immunomodulatory activity of sulindac plus erlotinib for colon cancer prevention in familial adenomatous polyposisPresenter/Authors
Chakrapani Tripathi, Roderick H. Dashwood. Texas A&M… read more
POSTED: 04/01/2022
SOURCE: DCP News
One of the first-ever vaccines for the prevention of colorectal and other cancers in patients at high genetic risk for these malignancies is expected to start its early phase safety and immunogenicity trial in the first quarter of 2022, according to investigators… read more
POSTED: 07/13/2021
SOURCE: Cancer Prevention Science Blog